Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
ASND Stock Chart & Stats
Day’s Range― - ―
52-Week Range$111.09 - $183.00
Previous CloseN/A
Volume129.18K
Average Volume (3M)432.35K
Market Cap
$10.56B
Enterprise Value$6.46B
Total Cash (Recent Filing)$559.54M
Total Debt (Recent Filing)€856.62M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Sep 09, 2025EPS Estimate
-1.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding60,970,566
10 Day Avg. Volume419,434
30 Day Avg. Volume432,346
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)24.28
Price to Sales (P/S)0.00
P/FCF Ratio-12.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$241.85Price Target Upside37.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Ascendis Pharma News
PremiumCompany Announcements
Ascendis Pharma’s Cancer Study Termination: Implications for Investors
PremiumCompany Announcements
Ascendis Pharma Grants Warrants to Employees to Boost EngagementBulls Say, Bears Say
Bulls Say
Market AdoptionStrong uptake of Yorvipath after the official U.S. launch provides compelling evidence to support its clinical benefit and further boost market adoption.
Product EfficacyThe 3-year eGFR data from Yorvipath’s phase III PaTHway trial reinforces a compelling profile in chronic hypoparathyroidism, showing sustained normalization of serum calcium and a durable benefit on kidney function.
Sales PerformanceAnalysts remain bullish on ASND’s performance, forecasting above-consensus worldwide Yorvipath sales despite conservative reimbursement assumptions.
Bears Say
Market UncertaintiesThere is potential for a strong Yorvipath quarter to trigger another round of upward estimate revisions.
Potential CompetitionThe potential competition from MBX 2109 is not seen as a significant risk due to Yorvi’s high efficacy and large market size, but strong MBX data could still impact ASND shares.
Prescription BarriersAccess to Yorvi is improving, with fewer doctors reporting new-to-market blocks as a barrier to prescribing compared to the last survey.
Ownership Overview
―
Insiders
31.93% Mutual Funds
0.21% Other Institutional Investors
66.44% Public Companies and Individual Investors
ASND FAQ
What was Ascendis Pharma’s price range in the past 12 months?
Ascendis Pharma lowest stock price was $111.09 and its highest was $183.00 in the past 12 months.
What is Ascendis Pharma’s market cap?
Ascendis Pharma’s market cap is $10.56B.
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s upcoming earnings report date is Sep 09, 2025 which is in 53 days.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on May 01, 2025. The company reported -$1.837 earnings per share for the quarter, missing the consensus estimate of -$1.706 by -$0.131.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate is -1.48.
How many shares outstanding does Ascendis Pharma have?
Ascendis Pharma has 60,970,566 shares outstanding.
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of -$1.837 in its last earnings report, missing expectations of -$1.706. Following the earnings report the stock price went up 2.741%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Currently, no hedge funds are holding shares in ASND
Ascendis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$241.85 (37.88% Upside)
$241.85 (37.88% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 189.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.51%
12-Months-Change
Fundamentals
Return on Equity
357.68%
Trailing 12-Months
Asset Growth
32.29%
Trailing 12-Months
Company Description
Ascendis Pharma
Ascendis Pharma A/S (ASND) is a biopharmaceutical company focused on improving patient outcomes through the development of innovative therapies. The company operates primarily in the healthcare sector, specializing in endocrinology and oncology. Its core products include TransCon growth hormone for pediatric growth hormone deficiency, and the company is also exploring treatments in other therapeutic areas using its proprietary TransCon technology platform, which allows for sustained release of drugs to improve efficacy and patient experience.
ASND Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights Ascendis Pharma's strong launch and revenue growth for YORVIPATH, alongside significant advances in their product pipeline. However, this success is tempered by increased operating expenses and ongoing challenges in securing insurance reimbursements. Overall, the sentiment is balanced with significant achievements and operational challenges.Read More>ASND Stock 12 Month Forecast
Average Price Target
$241.85
▲(37.88%Upside)